Company news
Oryzon Genomics Sa (BME:ORY) news
Oryzon Genomics Sa news releases on 6ix. Latest, Sep 29, 2026: ORYZON receives European Medicines Agency approval to initiate the HOPE-2 Phase II study…
Press releases & updates
ORYZON receives European Medicines Agency approval to initiate the HOPE-2 Phase II study of vafidemstat for the treatment of Phelan-McDermid Syndrome
September 29, 2026
ORYZON Receives European Medicines Agency Approval to Initiate the HOPE-2 Phase II Study of Vafidemstat for the Treatment of Phelan-McDermid Syndrome (PMS)
September 28, 2026
ORYZON Announces Notice of Allowance for U.S. Patent Application Covering Iadademstat Combination With Gilteritinib
August 31, 2026
Oryzon Genomics S A : reports financial results and corporate update for half year ended June 30th, 2026
July 27, 2026
ORYZON Announces U.S. Patent Grant for Vafidemstat in Borderline Personality Disorder (BPD)
July 8, 2026
Oryzon Genomics S A : raises €12 million and signs a financing agreement with COFIDES to strengthen its balance sheet and accelerate its clinical programs
July 1, 2026
ORYZON Presents Updated Positive Clinical Data for Iadademstat in Acute Myeloid Leukemia (AML) at European Hematology Association (EHA) 2026 Annual Congress
June 11, 2026
Oryzon Genomics S A : initiates patient enrollment in IDEAL Phase II trial of iadademstat in essential thrombocythemia
June 2, 2026
ORYZON Reports Financial Results and Corporate Update for Quarter Ended March 31st, 2026
May 14, 2026
ORYZON to Participate in Upcoming Events in May and June
April 29, 2026
ORYZON Strengthens Vafidemstat Patent Portfolio With U.S. Notice of Allowance
March 25, 2026
ORYZON Announces U.S. Patent Grant Covering Iadademstat Combinations with Venetoclax
March 23, 2026
ORYZON Expands Patent Protection for Iadademstat with Grant Decision in Mexico Covering Combinations with PD-1/PD-L1 Inhibitors
March 12, 2026
ORYZON Reports Financial Results and Corporate Update for Quarter Ended December 31st, 2025
February 27, 2026
ORYZON Receives European Medicines Agency Approval to Initiate a Phase II Study of iadademstat in Essential Thrombocythemia
February 24, 2026
ORYZON to Participate in Upcoming Events in February and March
February 19, 2026
ORYZON Announces Appointment of Rolando Gutierrez-Esteinou, M.D., as Chief Medical Officer for CNS
February 12, 2026
ORYZON Announces First Patient Dosed in an Investigator-Initiated Phase Ib Study of Iadademstat in Extensive Stage Small Cell Lung Cancer
February 9, 2026
ORYZON Strengthens Patent Portfolio for Vafidemstat With New Decision to Grant in Japan
February 2, 2026
ORYZON to Participate in Upcoming Events in January
January 8, 2026
ORYZON Expands Global Patent Protection for Iadademstat with Grant Decision in Japan Covering Combinations with PD-1/PD-L1 Inhibitors
December 22, 2025
ORYZON Announces the Voting Results of December 2025 Extraordinary General Shareholders' Meeting
December 15, 2025
ORYZON Presents Data for Iadademstat Combinations in AML at the American Society of Hematology (ASH) 67th Annual Meeting
December 9, 2025
ORYZON Reports Financial Results and Corporate Update for Quarter Ended September 30, 2025
November 7, 2025
ORYZON Announces Positive Clinical Data of Iadademstat at ASH-2025
November 4, 2025
ORYZON Announces First‑Patient‑In (FPI) in RESTORE Phase Ib Trial of Iadademstat in Sickle Cell Disease
November 3, 2025
ORYZON to Participate in Upcoming Events in November
October 30, 2025
ORYZON Strengthens Regulatory Strategy with the Appointment of Dr. Iman Barilero as Senior Advisor for Regulatory Affairs
October 28, 2025
ORYZON Receives Feedback From the FDA in Response to the Submitted Phase III Protocol in Borderline Personality Disorder
October 17, 2025
ORYZON Strengthens Patent Portfolio for iadademstat with European Grant Decision Covering Combinations with PD1/PD-L1 Inhibitors
October 1, 2025
ORYZON to Participate in Upcoming Events in September and October
September 25, 2025
ORYZON to Sponsor First Phelan-McDermid Syndrome (PMS) Burden of Illness Study
September 22, 2025
ORYZON Strengthens Patent Portfolio for Iadademstat and Vafidemstat with New Decisions to Grant
September 16, 2025
ORYZON Finalist at the 2025 European Lifestars Awards
September 4, 2025
ORYZON Receives European Medicines Agency Approval to Initiate a Phase Ib Study of Iadademstat in Sickle Cell Disease
August 25, 2025
ORYZON Reports Financial Results and Corporate Update for Half-Year Ending June 30, 2025
July 30, 2025
Expanding Analyst Interest in ORYZON
July 21, 2025
ORYZON Continues to Strengthen its Patent Portfolio for Vafidemstat
July 14, 2025
ORYZON to Host Virtual KOL Event on July 9, 2025
June 25, 2025
ORYZON Announces Submission of Phase III Protocol to FDA to Initiate PORTICO-2 Trial of Vafidemstat in Borderline Personality Disorder (BPD) Patients
June 23, 2025
ORYZON to Attend the 2025 Phelan-McDermid Syndrome (PMS) Congress in Barcelona on June 26-29
June 17, 2025
ORYZON to Provide Corporate Progress Updates at Several Events in May-June
May 27, 2025
ORYZON Reports Financial Results and Corporate Update for Quarter Ended March 31, 2025
May 12, 2025
ORYZON Awarded €13.26 Million Through the First Important Project of Common European Interest (IPCEI) in the Health Sector (Med4Cure Project)
May 8, 2025
ORYZON Raises €30 Million in Capital Increase
April 24, 2025
ORYZON Announces First Patient Dosed in NCI-Sponsored Phase I/II Clinical Trial of Iadademstat Plus Immune Checkpoint Inhibitors in 1L Extensive Stage Small Cell Lung Cancer
April 15, 2025
ORYZON to Provide Corporate Progress Updates at Several Events in March-April
March 14, 2025
Oryzon Announces Publication of Study on Phelan-McDermid Syndrome (PMS) Patients, a Form of Autism, Paving the Way for a Novel Personalized Medicine Approach with Vafidemstat
March 5, 2025
Oryzon Defines Phase III Trial Endpoints for Agitation and Aggression in BPD with Input From New Clinical Advisory Board
March 3, 2025
ORYZON Announces the Voting Results of February 2025 Extraordinary General Shareholders' Meeting
February 28, 2025